Research Group Leader, Senior Scientist | Member Workstream 1 and 4

Lars G. Hemkens, MD, MPH is the Lead of Pragmatic Trials and Real World Evidence at the Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB),a Professor for Clinical Epidemiology at the University of Basel and Senior Scientist at the Department of Clinical Research, University of Basel. Dr. Hemkens is affiliated with the Meta-Research Innovation Center at Stanford (METRICS; Stanford University, USA).

Previously, Dr. Hemkens was Deputy Director of the Basel Institute for Clinical Epidemiology and Biostatistics (ceb) until its closure, at the Stanford Prevention Research Center (Stanford University), and at the Institute for Quality and Efficiency in Health Care (IQWiG, Cologne, Germany; Department of the Director). At RC2NB, Dr. Hemkens leads the workstream Pragmatic Trials and Real World Evidence and the Pragmatic Evidence Lab. He develops and investigates digital biomarkers and digital health applications in multiple sclerosis and is Co-PI of MultiSCRIPT, a nationwide pragmatic platform trial fully embedded in the Swiss MS cohort as a learning healthcare system to continuously improve care of persons with multiple sclerosis.

At the Department of Clinical Research, he co-designs various clinical studies in a wide range of medical fields and closely supervises the design of nationwide investigator initiate clinical trials. Dr. Hemkens is associate editor and thematic series editor of “Big data for randomized trials” at Trials, sits on the editorial board of BMJ Evidence-Based Medicine, and the working committee of the RECORD reporting guideline group. Dr. Hemkens’ teaches comparative effectiveness research and pragmatic trial design at the University of Basel and Sorbonne Paris Cité, France.